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ABSTRACT
Tasosa, Joseph T., M.B.A., Department of Social and Applied Economics, Wright State
University, Dayton OH, 2004.
A Comparative Evaluation of the Cost Effectiveness of Treating the Metabolic Syndrome
in African Americans and the General Population1

•The Metabolic Syndrome poses an important public health threat to the U.S. health care
delivery system. Disparate access to quality health care makes African Americans
(blacks) especially susceptible to the adverse effects of MS. Although direct evidence
suggests that early treatment of MS risk factors saves lives, no study to date has
compared the cost effectiveness of such measures in blacks and the general population.
Interventions that promote early treatment of MS risk factors may improve public health
but could also lead to excess costs that are ultimately borne by society. The objective of
this study was to assess the value of early treatment of MS risk factors in blacks and the
general population. A cost effectiveness analysis was carried out using a Markov decision
model to compare early treatment and late treatment of MS risk factors in blacks and the
general population. The main outcome measure was the incremental cost per Quality
Adjusted Life Year (QALY). With the exception of early treatment of hyperlipidemia in
blacks ($ 187,462/QALY), early treatment of individual MS risk factors at age 30 was
found to be cost effective (<$27,000/QALY) for both blacks and the general population.
With the exception of treatment of hyperlipidemia, early treatment strategies targeted at
blacks were found to be more cost effective than those targeted towards the general
population. Sensitivity analyses indicated that age and cost of treatment were the most
influential factors in the model. The cost effectiveness of early treatment of MS risk
factors in blacks and the general population compares favorably with similar health care
interventions. The results support a growing body of literature that indicates the cost
effectiveness of providing preventative services to apparently healthy individuals.
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Introduction

Metabolic Syndrome

The Metabolic Syndrome (MS) is a group of risk factors
that are known to increase the incidence of cardiovascular
and renal disease.

These risk factors include abdominal

obesity, insulin resistance, hypertension and dyslipidemia
(Appendix A) . The impairment of the fibrinolitic system
and the presence of prothrombic and proinflammatory states
have also been cited as important components of MS.

The National Health and Nutrition Examination Survey
III (NHANES III, 1988-94) found 25% of all U.S. adults and
42% of those over the age of 60 have MS (Ford et al, 2002).
Despite the high prevalence, there is still no generally
accepted definition of MS (Scott, 2003).

Most experts

however, agree that the simultaneous presentation of three
of the four major risk factors is sufficient for defining
the MS (National Cholesterol Education Program Adult
Treatment Panel III 2001 [NCEP ATP III], Meigs, 2002).
a more detailed discussion on the history and issues
surrounding the definition of MS, see Appendix B.
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Racial Disparities in Health care

Racial disparities in health care are described as
"...racial or ethnic differences in the quality of health
care that are not due to access related factors, clinical
needs, preference, or appropriateness of intervention
(Smedley et al [eds], 2003)."

The Institute of Medicine

(2003) views racial disparities in the context of the legal
and regulatory climate of health care systems and in the
context of stereotyping and prejudice.

As cited by Williams and Collins (1994), disparities
in the provision of health care tend to diminish when
socio-economic factors are held constant.

Kitagawa and

Hauser (1973) support this idea by documenting diminishing
returns to health beyond a certain level of income.
Similarly House et al (1993) conclude that income related
health gains diminish for household incomes above $20,000
per year.

While these assertions may be true for access related
issues, Kressin and Petterson (2001) and Ofili (2000) argue
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that racial disparities remain even after an adjustment for
socio-economic status and other health care access related
factors are accounted for.

The extent of health disparities in the African
American (black) community has been extensively chronicled.
Such documentation indicates race as an important factor in
the diagnosis of MS risk factors. Blacks, for example, have
a reduced chance of being diagnosed of some risk factors
and therefore have a higher risk of cardiovascular disease
than do whites (Brancati et al, 2000; Karter et al, 2002).
As cited by Bell et al (2004), blacks are 1.97 times more
likely to have untreated hypertension than are whites even
after adjusting for socio-economic status.

Although racial and ethnic disparities in health care
are consistent across a wide range of diseases and health
care services (IOM, 2003), this study will focus on racial
disparities as they relate to the MS.

The purpose of this

project is to study the economic cost of treating MS risk
factors in blacks versus the general population.
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General Population
New standards were announced in 1997 for the
classification of individuals by race within the U.S.
Federal Government's national data systems (Freid et al,
2003). These standards classified individuals under five
main racial groups: American Indian or Alaska Native,
Asian, Black or African American, Native Hawaiian or
Pacific Islander and White. Race and Hispanic origin are
considered as two separate and distinct concepts, thus
Hispanics may be of any race. The general population in
this study contains individuals from all five racial
groups.
The purpose of this project is to study the economic
cost of treating MS risk factors in blacks versus the
general population at the national level thus national data
was used. National data was also used because it is the
most consistent and the most available.

Societal Perspective of Cost Effectiveness Analysis

Cost effectiveness analysis (CEA) is used by health
consumers to assess the relative value of different health
care services and by the health care industry to support
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marketing claims. CEA is particularly useful when policy
makers seek efficient policies but face certain constraints
that prevent them from doing the more traditional Cost
Benefit Analysis (Boardman et al, 2001). These constraints
include the inability to capture all the social costs of an
intervention (Gold et al, 1996). Social costs in our study
measure the loss of economic productivity associated with
MS outcomes.

Despite the importance, the loss of economic
productivity was not factored into our CEA because it is
difficult to quantify and could not be easily incorporated
into our model. The QALY our measure of effectiveness has
also been accused of not measuring social value because its
preferences and weights are based on an individualistic
perspective rather than a societal perspective (Drummond et
al, 2000). Since it is society that ultimately bears the
cost of health care, it would seem more appropriate if a
more socially sensitive unit is used to measure cost and
effectiveness.

When all social costs are captured, the

most allocatively efficient intervention becomes the most
cost effective.

5

Me thodology

Treatment Options and Clinical Outcomes

The progression path of the Metabolic Syndrome is
illustrated through a Markov decision tree diagram (Fig. 1A
and Fig. IB) constructed using DATA 4.0 (TreeAge Software,
Inc., Williamstown MA, USA).

The model is able to simulate

possible disease progression pathways by tracking a
theoretical group of blacks and another of the general
population at risk of the MS.

At the end of the simulation, the model calculates the
number of people alive under each pathway and the costs
involved.

The Markov model is also able to estimate

quality of life under each treatment option and the cost
effectiveness per Quality Adjusted Life Year (QALY) gained
(see Appendix B) as the groups move from one transition
state to another.

Two treatment options were identified,
treatment and (2) late treatment.
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(1) early

We assume that MS risk

factors in the late treatment option go untreated until a
major clinical outcome occurs. This is often the status
quo. Stroke, Myocardial Infarction (heart attack) and EndStage Renal Disease (ESRD) were chosen as the three major
clinical outcomes of MS because they can be easily
measured, they are the most prevalent and they are the most
sensitive to intervention.

The impact of Stroke, Myocardial Infarction (MI) and
ESRD can be reduced by early detection and treatment of the
major components of MS (Lakka et al, 2003; Berg et al,
2001). Our hypothesis assumes that we can drastically
reduce the negative impact of MS outcomes in blacks and the
general population if we are able to provide early and
aggressive treatment. This is especially important in the
context of eliminating racial disparities in health care
because reducing the negative impact of MS outcomes in
blacks may lead to a reduction in racial disparities in
health care.

7

F&l&l Slroks

S m m stroke
Mildeboka
F&lal MI

Won-filslMI

Lsevere slroks
L_ec¥»M slrok*
LjniM slroks
L JatalM l
] Lji0»-ftlal MI

Fig 1A: Markov Decision Tree—African American
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Fig IBs Markov Decision Tree—General Population
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Although the economic costs of providing early
treatment are high, these costs may be offset by increased
productivity and increased quality of life that arise from
early treatment.

In this study, the economic impact of

treating MS risk factors in blacks is compared to that of
treating the MS in the general population.

Subgroup Analysis

A target population may be separated into specific
subgroups that are expected to exhibit a different level of
effectiveness due to the intervention. Blacks are selected
as a subgroup of the general population because they have
different incidence and mortality rates. Although subgroup
analysis may be relevant to the decision maker, its
relevance must be weighed against the decreased precision
of available data (Gold et al, 1996). Blacks are chosen as
a subgroup because data on them is more readily available
compared to other racial minorities.
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Markov State Transition Model

Since some diseases and treatments are characterized
by repetitive events, it becomes difficult for an analyst
to portray this dynamic process in a static way (Drummond
et al, 2000).

The ability of the Markov model to represent

repetitive events and its ability to accommodate the time
dependence of both probabilities and utilities, allows it
to more accurately represent clinical settings.

Markov models make the assumption that a patient is
always in one of a finite number of health states also
called Markov states.

Events are represented as

transitions from one Markov state to the other.

Markov models are useful when the timing of
significant events is important and when these events are
likely to happen more than once.

Conventional decision

trees are unable to accurately represent such clinical
settings without over-simplifying model assumptions
(Sonnenberg and Beck, 1993) .

11

M ark ov H e a lth , S t a t e s

Individuals in a cohort fall into one of the following
definitive Markov states:
Severe stroke,
Fatal MI,

(1) Well (2) Mild stroke,

(4) Fatal stroke,

(7) ESRD,

(5) Non Fatal MI,

(3)
(6)

(8) Disability and (9) Death.

The model is used to calculate the proportion of the
cohort in each of the nine health states.

The Markov model

has a cycle time (the average amount of time spent in a
health state) of one year and can only account for one
transition between health states per year.

A cycle time of

one year is clinically meaningful even for rare events
(Sonnenberg and Beck, 1993) but it can be shortened for
more frequent events or for events that change rapidly
(Goldman, 1983).

The model allows for persons to move from one state to
another based on the transition probabilities of the two
possible pathways.

Transition probabilities help simulate

the progression of groups through all possible combinations
of events and outcomes over time.

The type of event, the

severity of the event and the age of an individual all
influence the transition probabilities (Elliot et al,
12

2000).

The severity of the event is in turn dependent upon

a predetermined ratio of all possible outcomes of this
event.

Individuals at the start of the simulation are assumed
to be well. Individuals who recover completely can move
back into the "well" state but individuals who become
disabled or develop ESRD do not recover completely as these
disease states are not regressive. A person in the well or
disabled state may make a transition to the terminal death
state. The death state (absorbing state) is the only state
that a patient cannot leave. All the other states are
temporary (See Fig. 2).
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Fig. 2: Markov State Diagram. Each circle indicates a
Markov state. Arrows indicate allowed transitions.
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Medical Costs

Only intensive treatment costs of hypertension,
hyperlipidemia and diabetes are used as these have the best
effect in improving health.

Costs are based on studies

done by the CDC Diabetes Cost Effectiveness Group (1998,
2002) and expressed in 2004 US dollars discounted at an
annual rate of 3% per year. A 3% social discount rate is
based on recommendations by the US Public Health Service
Panel on Cost-Effectiveness in Health and Medicine (Gold et
al, 1996: pp 233), on standard practice in economic
evaluation (Weinstein and Stason, 1977; Brouwer and van
Exel, 2004) and on related CEA studies (Busbee et al, 2003;
Arguedas et al, 2004; Hoeger et al, 2004).

Costs of treating events are obtained from Elliot et
al (2000).

All costs are adjusted for inflation based on

US Bureau of Labor Statistics inflation calculator and are
listed in Table 1.
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Table Is Annual Costs of adverse events and treatment for
30 year old

Variable

Annual '

Cost of Disability

$49,181

Cost of ESRD

$42,461

Cost of Fatal Myocardial Infarction

$19,097

Cost of Fatal Stroke

$28,354

Cost of Mild Stroke

$14,172

Cost of Non fatal Myocardial Infarction

$38,215

Cost of Non fatal Stroke

$56,750

Cost of Hyperlipidemia Treatment

$ 1,638

Cost of Diabetes Treatment

$ 1,228

Cost of Hypertension Treatment

1Elliot et al (2000)
2 CDC Diabetes Cost-effectiveness Group
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$ 701

Prevalence Rates and Mortality Rates

The annual age related incidence of Stroke, MI, and
ESRD are obtained from studies done by Williams (2001),
U.S. Renal Data System (2003) and Wolf et al (1992) and are
applicable to the general population.

Age specific mortality rates for the general
population were estimated using 2000 U.S. life tables
(Freid, et al, 2003) and these varied by race. As cited by
(IOM, 2003) blacks have a 78% greater risk of mortality
than the general population.

Our assumption is that the

excess mortality due to racial disparities in the provision
of health care is 78% higher than that of the general
population.

Research also found the mortality rate of

individuals with the MS to be twice as great as that of the
average age, sex and race (ASR) adjusted mortality rate
(Golan et al, 1999).

These assumptions were incorporated

into the life tables to estimate the impact of MS risk
factors on mortality.

The adjusted hazard ratios for blacks (relative to
that of whites) were 2.03 for ESRD (Karter et al, 2002) and
17

1.40 for Stroke (Pfizer, 2003). These hazard ratios were
used to estimate the excess prevalence of ESRD and Stroke
in blacks and the excess mortality in blacks due to ESRD
and Stroke. Disability rates were derived from the US
Social Security Database.

Although individuals with ESRD or disability are at an
increased risk of having another event such as stroke or MI
(Reaven et al, 1996), these effects have not been factored
into the model, as literature on the event probabilities of
such scenarios is not conclusive.

We also know that

individuals with multiple risk factors are at an increased
risk of death than those without (Elliot et al, 2000). The
synergistic effects of having multiple risk factors have
however not been factored into the model.

Health utilities

Health utilities are cardinal values that enable
researchers to measure health related quality of life under
conditions of uncertainty.

Health utilities provide a

means to quantitatively measure and compare two health
states.

The standard gamble approach, the time trade-off
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approach, rating scales and the willingness to pay approach
are some of the methods used to calculate health utilities
(Petrou, 2003).

For a brief discussion on the standard

gamble approach see Appendix D.

Defining a set of health states is the first step in
measuring health utilities.

Each health state is assigned

a utility value between 0 and 1 whose endpoints are death
and perfect health. Our study uses utility values developed
by Rizzo et al (1998) and CDC Diabetes Cost effectiveness
Group (2002).

Stroke is assigned a value of 0.5, MI 0.88,

ESRD 0.61 and disability 0.46. These utility values are
then used to estimate QALYs. Since health utilities are
relative values, we can assume that they are affected by
age, sex, culture, socio-economic status and race.

The

utility values used in this analysis however, are not race
specific because such data is unavailable.

With the use of transition probabilities and utility
of life measures associated with each treatment option, the
model calculates the cost effectiveness of early treatment
of MS in blacks and the general population. The simulation
automatically terminates when individuals turn 77 or die.
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Seventy-seven years is the life expectancy in the U.S.

At

the end of the simulation a group of 30 year olds was used
as the base case to estimate parameters for both blacks and
the general population.

Results

Base Case Analysis

Blacks

The incremental cost per QALY is the additional costs
that early treatment imposes over late treatment for each
QALY gained (status quo).

Early treatment of hypertension,

hyperlipidemia and diabetes together in 30-year-old blacks
came at an estimated incremental cost of $53,140/QALY
gained.

Early treatment of hyperlipidemia alone came at an

estimated incremental cost of $187,462/QALY gained, while
early treatment of diabetes alone and hypertension alone
came at an incremental cost of $11,755 and $2,456 per QALY
gained respectively (Table 2A).
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Table 2A: Cost/QALY Blacks

Age All Three Hyperlipidemia Diabetes Hypertension
20

78,816

121,393

19,939

7, 612

30

53,140

187,462

11,755

2, 456

40

36,363

517,696

5, 396

**

50

23,259

*

224

**

60

14,840

★

**

**

70

11,879

316,337

kk

*k

* Late treatment dominated early treatment
** Early treatment dominated late treatment

Dominance

When choosing between two alternatives, we first apply
the principle of strong dominance. One program is said to
dominate another if its effectiveness were higher and its
costs lower. In this case it is unnecessary to calculate a
cost-effectiveness ratio (Gold et al, 196). As shown in
Table 2A late treatment of hyperlipidemia in blacks
dominated early treatment at age 50 and 60.
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The additional

cost of early treatment of hyperlipidemia is not met with
any additional improvement in the quality of life of blacks
at this age. It is therefore more cost effective to
maintain the status quo and not to employ any early
treatment strategies targeted towards blacks in this age
group.

Early treatment of diabetes in blacks dominated

late treatment at age 60 and 70 and early treatment of
hypertension dominated late treatment in blacks over the
age of 40.
General population
Early treatment of hypertension, hyperlipidemia and
diabetes together in a 30-year-old member of the general
population came at an estimated incremental cost of
$63,926/QALY gained.

Early treatment of hyperlipidemia

alone came at an estimated incremental cost of $26,243/QALY
gained, while early treatment of diabetes alone and
hypertension alone came at an incremental cost of $17,789
and $6,290 per QALY gained respectively (Table 2B).

With the exception of hyperlipidemia, the incremental
cost per QALY gained by early treatment of MS risk factors
was lower in blacks than it was in the general population.
In general, this evidence suggests that early treatment of

22

MS risk factors in blacks

is more cost effective than it is

for the general population. Since we assume that blacks are
more prone to the effects of MS than the general
population, it follows that each additional dollar spent on
preventative treatment of diabetes and hypertension in
blacks saves more lives than each additional dollar spent
on treating the same risk factors in the general
population. The high cost of aggressive treatment of
hyperlipidemia in blacks and the relatively low impact of
this treatment however, makes it cost-ineffective relative
to the general population.

Table 2Bs Cost/QALY General Population

Age All Three Hyperlipidemia

Diabetes

Hypertension

20

94,414

39,168

27,599

12,355

30

63, 926

26,243

17,789

6, 290

40

41,084

16,291

10,240

**

50

25,412

8, 852

4, 602

**

60

16,662

4, 641

1, 741

**

70

14,213

4, 059

2, 051

**

** Early treatment dominated late treatment
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When early treatment is more effective but less costly
than late treatment, it is said to dominate. In our results
early treatment of hypertension is dominant over late
treatment for individuals over 40 (Table 2B). Individual
over 50 are the most prone to MS outcomes and so benefit
the most from early treatment. Treating hypertension early
may avoid the costly health problems it may cause if left
untreated. As cited by the US Preventative Services Task
Force, the complications due to hypertension are among the
most common and most serious diseases in the U.S. Screening
for hypertension is thus recommended for all children and
adults.

Sensitivity Analysis

A one-way sensitivity analysis for the treatment of
diabetes, hyperlipidemia and hypertension identified age
and treatment costs as influential variables. The ranges
used in the sensitivity analyses are specified in (Table
3) .
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Table 3: Variables Used in Sensitivity Analysis

Variable
Age

Base-case

Range

30

20-77

702

282-822

Treatment Cost ($):
Hypertension
Diabetes

1, 228

Hyperlipidemia

1638

1 03 2,-.,
636-2 223

Varying the age

Treating MS risk factors in younger individuals was
found to be more effective than treating the same risk
factors in older individuals. This is because early
detection of disease is associated with substantial
increases in the quality of life.

Although intensive

treatment of MS risk factors is more effective for younger
people, it came at an increased cost to society.

Treating

MS risk factors in younger individuals saved more lives
than it did in older individuals. These results confirm our
assumptions that preventive treatment strategies that start
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early on in life are a more cost effective approach than
are late treatment strategies. These data also complement
studies that have shown that the majority of deaths below
the age of 65 are preventable through interventions easily
provided in a clinician's office (U.S. Preventive Services
Task Force, 1996).

Treatment of hypertension, hyperlipidemia and diabetes
together from age 20 resulted in 25 lives saved per year
among blacks and 26 lives saved per year among the general
population.

The additional number of lives saved in the

U.S. from age 20 to 70 dropped to 11.76 per year in blacks
and to 12 per year in the general population.

This was a

drop of 53.6% in blacks and 53.8% in the general
population.

Varying Costs

Increasing treatment costs decreased the cost
effectiveness of treating MS risk factors.

Conversely,

reducing treatment costs resulted in a higher cost
effectiveness. The incremental cost for the treatment of
diabetes in blacks ranged between $9,346/QALY and
$14,165/QALY, treatment of hypertension was between
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$2,190/QALY and $4,582/QALY and treatment of hyperlipidemia
between $116,159/QALY and $229,518/QALY.

The incremental cost for the treatment of diabetes in
the general population ranged between $23,685/QALY and
$31,513/QALY, treatment of hypertension was between
$140/QALY and $8,880/QALY and treatment of hyperlipidemia
between $4,783/QALY and $38,901/QALY.

We did not attempt

to do a sensitivity analysis for the treatment of all three
risk factors because data on the appropriate limits is
unavailable.

Discussion

Discounting is one of the prominent topics of debate
in health economics as the idea that money today is worth
more than money tomorrow also extends into health care
analysis. Traditionally there have been two competing
theories regarding the social discount rate: the social
opportunity cost theory and the social rate of time
preference theory (Drummond et al, 2000). While we have
used a constant discount rate (social rate of time
preference) of 3% in our analysis, this standard practice
27

by Weinstein and Stason (1977) has been criticized by some
who argue that it does not fairly reflect a timeless
societal preference for health and wealth, that is,
individuals do not discount at constant rates (Cairns and
van der Pol, 1996; Harvey, 1994, Brouwer and van Exel,
2004). Still others argue that there are differences
between societal time preferences and individual time
preferences (Olsen, 1993) and that costs and effects should
be discounted at different rates (Gold et al, 1996).

While these arguments are compelling, we decided to
follow the recommendations of the US Public Health Service
Panel on Cost-Effectiveness in Health and Medicine (Gold et
al, 1996). This expert panel argued that costs and effects
should be discounted at a rate consistent with the shadowprice-of-capital approach to evaluating public investments.
Given currently available data on real economic growth and
given corresponding estimates of the real interest rate,
the panel agreed that a rate of 3% would most closely
estimate the real (riskless) discount rate for CEA.

Since CEA measures technical efficiency, rather than
allocative efficiency it cannot easily indicate whether
something is worth doing (Boardman et al, 2001). Hadley and
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Holahan (2003) address this problem by choosing the annual
cost it takes to treat ESRD as the de facto standard cost
by which society in the U.S. is willing to pay for a health
care intervention. Their assumption is based on the fact
that MEDICARE, a federal health insurance program designed
to provide health care for the elderly and the disabled
also supports ESRD patients.

The incremental cost per QALY of most of the
interventions in this study fall below the $42,400/QALY it
takes to treat an ESRD patient. This is true for the
treatment of hyperlipidemia, diabetes and hypertension for
all ages in the general population and for the treatment of
diabetes and hypertension for all ages in blacks. The
incremental cost per QALY was below $42,400/QALY when all
three MS risk factors were treated in blacks above 40
years. It was also below $42,400/QALY when all three MS
risk factors were treated in the general population above
50.

It can be hypothesized that U.S. society is willing to

pay for these interventions.

Early treatment of hypertension among blacks proved to
be the most cost effective option. It is clear that
mortality from several common and serious diseases can be
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lowered through the detection and treatment of high blood
pressure. As cited by Collins et al (1990), a reduction in
diastolic BP by 5-6 mm Hg in hypertensive patients could
reduce the accidence of coronary heart disease by 14% and
incidence of strokes by 42%. Since blacks are especially
prone to hypertension, its late treatment ultimately leads
to massive increases in the health care costs borne by
society.

Early treatment of hyperlipidemia in blacks proved to
be the least cost effective option.

This was because the

high cost of aggressive treatment of hyperlipidemia did not
result in a significant improvement in the quality of life
among blacks. Our results complement recommendations set by
the U.S. Preventive Task Force (1996), which found no
sufficient benefits in routine screening of hyperlipidemia
in children, adolescents, or young adults.

We found that at all ages and all costs in the
general population, treatment of hypertension,
hyperlipidemia and diabetes together was less cost
effective than targeting a single risk factor. This is
because the added cost in treating all three risk factors
did not significantly improve the quality of life. In
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general, screening for hypertension was the most cost
effective option, followed by diabetes screening and
hyperlipidemia screening.

The values estimated in this study compare favorably
to federally mandated health care interventions. In a study
that looked at the cost effectiveness of 587 public health
care interventions in the U.S., Tengs et al (1996) found
that the overall median intervention costs were about
$42,000/QALY. The median medical intervention cost was
$19,000/QALY; injury reduction $48,000/QALY; and toxin
control $2,800,000/QALY.

Our results also compare well to cost effectiveness
analyses carried out by Graham et al (1997) and Groeneveld
et al (2001). Graham et al (1997) by looking at "The cost
effectiveness of airbags by seating position," in a
federally mandated program, demonstrated that driver side
airbags have a cost effectiveness of $30,000/QALY while
passenger side airbags save lives at a cost of
$76,500/QALY. Groeneveld et al (2001) concluded that the
incremental cost effectiveness of full Automated External
Defibrillator deployment on commercial aircraft ranged
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between $ 35,300 and $ 94,700 per QALY. Some major aircraft
carriers have now deployed AED's in their aircraft.

Limitations

Although our economic analysis satisfied most of the
criteria critical for a robust evaluation (Drummond et al,
2000; pp 27-51), we identified significant limitations.

The unavailability of reliable literature on the
combined costs and effects of treating MS risk factors
proved to be a big limitation.

Although some studies have

been performed to investigate the differences in MS event
rates among the different races and ethnicities in the
U.S., we are to our knowledge the first to compare the cost
effectiveness of treating MS risk factors in blacks and the
general population. Our study would have benefited had we
been able to access similar studies and their associated
data.

Another limitation is that our assumptions consider
late term treatment as no treatment at all.

This is not

the case in the model as we have incorporated the effects
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of moderate treatment into late treatment. Our decision to
do this reflects our realization that, in reality, most at
risk individuals do receive some sort of treatment over
time and thus a strictly "no treatment" option is
impractical.

Accuracy in the analysis can be improved if

late treatment is actually modeled as no treatment at all.
This issue may be addressed by a sensitivity analysis that
varies the costs of late treatment.

Our initial study did

not carry out this sensitivity analysis because we felt it
would overly complicate our model.

The model assumes that patients in the early treatment
group will follow an aggressive treatment regimen.

The

model does not allow for external factors such as noncompliance, discontinuation of treatment, adoption of other
therapies or lifestyle adjustment.

Lifestyle adjustments

such as diet, physical inactivity, and nicotine and alcohol
consumption play an important role in the manifestation of
MS (Regenauer, 1996).

Our model does not incorporate clinical events that
occur before diagnosis and assumes that individuals are in
perfect health at the start of the treatment regimen. The
model also assumes that treatment of MS begins at the onset
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of the syndrome.

In practice, individuals are not in

perfect health at the start of treatment. In addition,
treatment can only begin after clinical diagnosis.

One weakness of the Markov Model is that it requires
rigid assumptions such as zero memory. With zero memory the
transition probabilities depend only on the individual's
current health state and not on prior events (Drummond et
al, 2000; Beck and Pauker, 1983). If the model cannot refer
to prior events in its analysis, it cannot adequately
incorporate the interaction of risk factors over time.

Zero memory is a severe limitation because each of the
MS components is known to be a risk factor for other
conditions.

As cited by Reaven et al (1996) and Zavaroni

(1999), risk factors in combination, significantly increase
the chance of developing potentially life-threatening
illnesses such as ESRD, MI and stroke. Furthermore, having
one component of MS increases your chances of having other
components of the syndrome.

The more components of MS one

exhibits the greater is ones risk of CVD.

Studies have

indicated that men with three MS risk factors are nearly
twice as likely to have a MI or stroke and more than three
times more likely to develop heart disease than those with
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none.

Men with four or five factors face four times the

risk of MI and stroke and more than 24 times the risk of
diabetes (Lakka et al, 2002).

Though the model adequately represents event incidence
and mortality as a function of age, it does not address
event incidence as a function of gender.

This is a severe

limitation because prevalence of MS is about 57% higher in
black women than it is in black men.

More accurate results

could be obtained from our analysis if gender was used as a
subgroup in both blacks and the general population.

While cost benefit analysis is generally considered to
be the preferred choice for valuing economic projects or
policies (Boardman et al, 2001), economic evaluation in
health care is often based on CEA criterion of dollars per
QALY (Blomqvist, 1998).

The QALY however, is not a perfect

measure of health outcomes and has been criticized on both
technical and ethical grounds.

Scholars point out that the

QALY is a needlessly complex approach that should be
replaced by a more straightforward measure of
effectiveness.

Still others argue that the QALY is overly

theoretical and should be replaced by simpler and more
practical methods (Blomqvist, 1998; Garber and Phelps,
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1997; Weinstein, 1995; Meltzer, 1997; Prieto and Sacristin,
2003, Doctor et al, 2004; Moatii et al 1995). For a brief
discussion on the QALY and its alternatives see Appendix B.

Treatment costs used in the model were derived from
1997 dollars and adjusted for inflation to represent 2004
dollars. Costs are then discounted at a constant rate of 3%
per year until the patient dies. Although standard practice
in economic analysis allows us to discount costs and
effects alike at a constant rate of 3-5%, many have raised
questions about this practice (Brouwer and van Exel, 2004).
According to the National Coalition on Health Care, health
care inflation is increasing at a rate that is five times
the inflation rate.

It follows that discounting at a

constant rate of 3% cannot accurately estimate future
treatment costs and effects, as it cannot adequately
address changes in health care inflation, changes in
treatment quality, changes in treatment standards and
changes in technology. An alternative method to using pre
set discount rates may be to use a more qualitative
approach to time preference. This method should incorporate
diminishing marginal utility for health and wealth when
calculating time preference (Brouwer and van Exel (2004) .
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It can be argued that, with the exception of death,
health utilities vary over time. The health utilities for
each of the nine health states in our model are constant
and are therefore unable to accurately measure the true and
dynamic nature of health utilities. We used constant rates
of health utilities rate because data on variable rates is
unavailable.

Conclusion

Early treatment of individual MS risk factors in
blacks and the general population saves lives in a cost
effective manner when compared to other health care
interventions.

With the exception of targeting

hyperlipidemia in blacks, targeting individual MS risk
factors was found to be more cost effective than targeting
all three risk factors (hypertension, hyperlipidemia and
diabetes) together. Targeting hyperlipidemia was found to
be less cost effective than treating all three risk factors
together.

Our cost effectiveness analysis is sufficiently robust
even when age and treatment costs are varied.
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With the

exception of hyperlipidemia treatment in blacks, changes in
age and treatment cost did not increase the cost
effectiveness beyond $42,400/QALY when individual risk
factors were targeted.

Although many health care studies have shown that
racial and ethnic disparities exist, less attention has
been given to identifying strategies to lessen these
disparities.

Our analysis while not directly applicable

beyond the early and late treatment of MS, can guide
similar analyses and strategies that look to address racial
disparities in health care.

The results shown in this

study support a growing body of literature that indicates
the cost effectiveness of providing preventative services
to apparently healthy patients (US Preventative Services
Task Force, Guide to Clinical Preventative Services).

38

Appendices

Appendix A

Metabolic Syndrome

A person with at least three of the following
cardiovascular risk factors is clinically diagnosed of
having MS (NHANES ATP III):
- Abdominal obesity: waist circumference of > 102
cm (40 inches) in men and > 88 cm (35 inches)
in women
- Hypertriglyceridemia: >=150 mg/dL (1.69
mmol/cm)
- Low High Density Lipoprotein (HDL) cholesterol:
<40 mg/dL (1.04 mmol/L) in men and <50 mg/dL
(1.29 mmol/L) in women
- High blood pressure: >= 130/85 mm Hg
- High fasting glucose: >=110 mg/dL (>=6.1
mmol/L)
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Appendix B
Discussion on the Definition of MS

In the late 1960s, the MS was described as a "disorder
of genetic adaptation becoming manifest following
unrestricted food intake and/or muscular inactivity"
(Hauner, 2002).

The clustering of cardiovascular risk

factors has since been given different names including
Insulin Resistance Syndrome, Syndrome X, Dysmetabolic
Syndrome, Multiple Metabolic Syndrome and Plurimetabolic
Syndrome (Isoma et al, 2001 and Meigs, 2003).

More

recently MS has been called the "deadly quartet" to
emphasize its high artherogenic potential (Hanefeld,
Leonhardt and Kaplan; Hauner, 2002).

In 1998 The World Health Organization (WHO),
which many consider as the primary authority on public
health policy, formulated a different definition of MS.
According to the WHO consultation for the classification of
diabetes and its complications (Alberti and Zimmet, 1998)
MS is composed of insulin resistance in combination with
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two or more of the following cardiovascular risk factors:
hypertension, obesity, dyslipidemia and microalbuminuria.

Emphasis on diabetes as a risk factor differentiates
the NCEP ATP III from the WHO definition of MS.

While WHO

and other studies (Lakka et al, 2002) maintain that
diabetes is the main factor of the MS, others think it is a
consequence of the MS (Ford et al, 2002).

Although most scholars agree that obesity is a risk
factor for cardiovascular disease, it is still unclear
whether this risk can best be estimated by Body Mass Index
(BMI) or abdominal obesity (Gus et al, 2004). WHO employs
the use of Body Mass Index (BMI) to diagnose MS, while the
NCEP ATP III favors waist circumference or abdominal
obesity to diagnose MS.

Lakka et al (2002) compared the accuracy of the NCEP
ATP III and the WHO definition of MS and concluded that the
WHO definition had a higher accuracy in predicting
cardiovascular risk and overall mortality associated with
MS.

Despite the findings of Lakka et al (2002), we believe

that abdominal obesity is a better indicator of
cardiovascular risk than is BMI.
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Our belief is supported by an extensive study showing
the prevalence of MS in the U.S.

(Ford et al, 2002).

Our

belief is also supported by Gus et al (2004) who conclude
that the risk of hypertension may be better identified by
obesity defined by higher waist circumference than higher
BMI.

For these reasons, we adopt the NCEP ATP III

definition of MS.

Still others feel that neither BMI nor waist
circumference is particularly useful in diagnosing MS
(Schubert, 2004). Instead, a high triglyceride level has
been cited as a more precise predictor of MS and CVD,
especially in cases when an individual may appear nonsymptomatic or in cases where there is variation in body
shape due to ethnicity (He et al, 2001) .
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Appendix C
Quality Adjusted Life Years

A QALY is a health index that estimates the quantity
and quality of life generated by health care interventions.
QALYs place weight on the time spent in different health
states such that a year of perfect health is assigned a
value of 1 and death is assigned a value of 0.

Some health

states are considered worse than death and are assigned
negative scores (Thompson (2003).

Weinstein and Stason (1977) popularized the term QALY.
QALYs are also referred to as Years of Healthy Life (YHL),
Health Adjusted Person Years (HAPY), Health Adjusted Life
Expectancy (HALE)
Saved (LYS).

(Drummond et al, 2000) and Life-Year

Several other alternatives to QALYs exist.

These include Health Year Equivalents (HYE) and SavedYoung-Life Equivalents (SAVE).

While the HYE has been proposed as a theoretically
superior alternative to the QALY albeit more complex to
execute, the SAVE has been proposed as a more socially
sensitive alternative because it reflects a societal
43

perspective to health utility. QALYs are accused of not
measuring social value because preferences and weights are
based on individualistic perspective rather than a societal
perspective (Drummond et al, 2000; Mehrez and Gafni, 1992
and Nord et al, 1993). Since it is society that ultimately
bears the cost of health care, it would seem more
appropriate if the SAVE is used to measure effectiveness.
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Appendix D

Standard Gamble Approach

When calculating health utilities under the standard
gamble approach (von Neumann and Morgenstern, 1953), an
individual is presented with two choices:

(1) the certainty

of survival for a specific period of time in a particular
state of health and (2) the gamble of survival for the same
period of time without disability on one hand and with
immediate death on the other.

The chance of survival

without disability, as opposed to the chance of death is
varied until the individual is indifferent between
certainty and gambling. This probability then estimates the
utility of the individual for the disabled state (Petrou,
2003) .
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between $ 35,300 and $ 94,700 per QALY. Some major aircraft
carriers have now deployed AED's in their aircraft.

Limitations

Although our economic analysis satisfied most of the
criteria critical for a robust evaluation (Drummond et al,
2000; pp 27-51) , we identified significant limitations.

The unavailability of reliable literature on the
combined costs and effects of treating MS risk factors
proved to be a big limitation.

Although some studies have

been performed to investigate the differences in MS event
rates among the different races and ethnicities in the
U.S., we are to our knowledge the first to compare the cost
effectiveness of treating MS risk factors in blacks and the
general population. Our study would have benefited had we
been able to access similar studies and their associated
data.

Another limitation is that our assumptions consider
late term treatment as no treatment at all.

This is not

the case in the model as we have incorporated the effects
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of moderate treatment into late treatment. Our decision to
do this reflects our realization that, in reality, most at
risk individuals do receive some sort of treatment over
time and thus a strictly "no treatment" option is
impractical.

Accuracy in the analysis can be improved if

late treatment is actually modeled as no treatment at all.
This issue may be addressed by a sensitivity analysis that
varies the costs of late treatment.

Our initial study did

not carry out this sensitivity analysis because we felt it
would overly complicate our model.

The model assumes that patients in the early treatment
group will follow an aggressive treatment regimen.

The

model does not allow for external factors such as noncompliance, discontinuation of treatment, adoption of other
therapies or lifestyle adjustment.

Lifestyle adjustments

such as diet, physical inactivity, and nicotine and alcohol
consumption play an important role in the manifestation of
MS (Regenauer, 1996).

Our model does not incorporate clinical events that
occur before diagnosis and assumes that individuals are in
perfect health at the start of the treatment regimen. The
model also assumes that treatment of MS begins at the onset
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of the syndrome.

In practice, individuals are not in

perfect health at the start of treatment. In addition,
treatment can only begin after clinical diagnosis.

One weakness of the Markov Model is that it requires
rigid assumptions such as zero memory. With zero memory the
transition probabilities depend only on the individual's
current health state and not on prior events (Drummond et
al, 2000; Beck and Pauker, 1983). If the model cannot refer
to prior events in its analysis, it cannot adequately
incorporate the interaction of risk factors over time.

Zero memory is a severe limitation because each of the
MS components is known to be a risk factor for other
conditions.

As cited by Reaven et al (1996) and Zavaroni

(1999), risk factors in combination, significantly increase
the chance of developing potentially life-threatening
illnesses such as ESRD, MI and stroke. Furthermore, having
one component of MS increases your chances of having other
components of the syndrome.

The more components of MS one

exhibits the greater is ones risk of CVD.

Studies have

indicated that men with three MS risk factors are nearly
twice as likely to have a MI or stroke and more than three
times more likely to develop heart disease than those with
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none. Men with four or five factors face four times the
risk of MI and stroke and more than 24 times the risk of
diabetes (Lakka et al, 2002).

Though the model adequately represents event incidence
and mortality as a function of age, it does not address
event incidence as a function of gender.

This is a severe

limitation because prevalence of MS is about 57% higher in
black women than it is in black men. More accurate results
could be obtained from our analysis if gender was used as a
subgroup in both blacks and the general population.

While cost benefit analysis is generally considered to
be the preferred choice for valuing economic projects or
policies (Boardman et al, 2001), economic evaluation in
health care is often based on CEA criterion of dollars per
QALY (Blomqvist, 1998).

The QALY however, is not a perfect

measure of health outcomes and has been criticized on both
technical and ethical grounds.

Scholars point out that the

QALY is a needlessly complex approach that should be
replaced by a more straightforward measure of
effectiveness.

Still others argue that the QALY is overly

theoretical and should be replaced by simpler and more
practical methods (Blomqvist, 1998; Garber and Phelps,
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1997; Weinstein, 1995; Meltzer, 1997; Prieto and Sacristin,
2003, Doctor et al, 2004; Moatii et al 1995). For a brief
discussion on the QALY and its alternatives see Appendix B.

Treatment costs used in the model were derived from
1997 dollars and adjusted for inflation to represent 2004
dollars. Costs are then discounted at a constant rate of 3%
per year until the patient dies. Although standard practice
in economic analysis allows us to discount costs and
effects alike at a constant rate of 3-5%, many have raised
questions about this practice (Brouwer and van Exel, 2004).
According to the National Coalition on Health Care, health
care inflation is increasing at a rate that is five times
the inflation rate.

It follows that discounting at a

constant rate of 3% cannot accurately estimate future
treatment costs and effects, as it cannot adequately
address changes in health care inflation, changes in
treatment quality, changes in treatment standards and
changes in technology. An alternative method to using pre
set discount rates may be to use a more qualitative
approach to time preference. This method should incorporate
diminishing marginal utility for health and wealth when
calculating time preference (Brouwer and van Exel (2004).
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It can be argued that, with the exception of death,
health utilities vary over time. The health utilities for
each of the nine health states in our model are constant
and are therefore unable to accurately measure the true and
dynamic nature of health utilities. We used constant rates
of health utilities rate because data on variable rates is
unavailable.

Conclusion

Early treatment of individual MS risk factors in
blacks and the general population saves lives in a cost
effective manner when compared to other health care
interventions.

With the exception of targeting

hyperlipidemia in blacks, targeting individual MS risk
factors was found to be more cost effective than targeting
all three risk factors (hypertension, hyperlipidemia and
diabetes) together. Targeting hyperlipidemia was found to
be less cost effective than treating all three risk factors
together.

Our cost effectiveness analysis is sufficiently robust
even when age and treatment costs are varied.
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With the

exception of hyperlipidemia treatment in blacks, changes in
age and treatment cost did not increase the cost
effectiveness beyond $42,400/QALY when individual risk
factors were targeted.

Although many health care studies have shown that
racial and ethnic disparities exist, less attention has
been given to identifying strategies to lessen these
disparities.

Our analysis while not directly applicable

beyond the early and late treatment of MS, can guide
similar analyses and strategies that look to address racial
disparities in health care.

The results shown in this

study support a growing body of literature that indicates
the cost effectiveness of providing preventative services
to apparently healthy patients (US Preventative Services
Task Force, Guide to Clinical Preventative Services).
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Appendices

Appendix A

Metabolic Syndrome

A person with at least three of the following
cardiovascular risk factors is clinically diagnosed of
having MS (NHANES ATP III):
- Abdominal obesity: waist circumference of > 102
cm (40 inches) in men and > 88 cm (35 inches)
in women
- Hypertriglyceridemia: >=150 mg/dL (1.69
mmol/cm)
- Low High Density Lipoprotein (HDL) cholesterol:
<40 mg/dL (1.04 mmol/L) in men and <50 mg/dL
(1.29 mmol/L) in women
- High blood pressure: >= 130/85 mm Hg
- High fasting glucose: >=110 mg/dL (>=6.1
mmol/L)
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Appendix B
Discussion on the Definition of MS

In the late 1960s, the MS was described as a "disorder
of genetic adaptation becoming manifest following
unrestricted food intake and/or muscular inactivity"
(Hauner, 2002).

The clustering of cardiovascular risk

factors has since been given different names including
Insulin Resistance Syndrome, Syndrome X, Dysmetabolic
Syndrome, Multiple Metabolic Syndrome and Plurimetabolic
Syndrome (Isoma et al, 2001 and Meigs, 2 003) . More
recently MS has been called the "deadly quartet" to
emphasize its high artherogenic potential (Hanefeld,
Leonhardt and Kaplan; Hauner, 2002).

In 1998 The World Health Organization (WHO),
which many consider as the primary authority on public
health policy, formulated a different definition of MS.
According to the WHO consultation for the classification of
diabetes and its complications (Alberti and Zimmet, 1998)
MS is composed of insulin resistance in combination with
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two or more of the following cardiovascular risk factors:
hypertension, obesity, dyslipidemia and microalbuminuria.

Emphasis on diabetes as a risk factor differentiates
the NCEP ATP III from the WHO definition of MS.

While WHO

and other studies (Lakka et al, 2002) maintain that
diabetes is the main factor of the MS, others think it is a
consequence of the MS (Ford et al, 2002).

Although most scholars agree that obesity is a risk
factor for cardiovascular disease, it is still unclear
whether this risk can best be estimated by Body Mass Index
(BMI) or abdominal obesity (Gus et al, 2004). WHO employs
the use of Body Mass Index (BMI) to diagnose MS, while the
NCEP ATP III favors waist circumference or abdominal
obesity to diagnose MS.

Lakka et al (2002) compared the accuracy of the NCEP
ATP III and the WHO definition of MS and concluded that the
WHO definition had a higher accuracy in predicting
cardiovascular risk and overall mortality associated with
MS.

Despite the findings of Lakka et al (2002), we believe

that abdominal obesity is a better indicator of
cardiovascular risk than is BMI.

41

Our belief is supported by an extensive study showing
the prevalence of MS in the U.S.

(Ford et al, 2002).

Our

belief is also supported by Gus et al (2004) who conclude
that the risk of hypertension may be better identified by
obesity defined by higher waist circumference than higher
BMI.

For these reasons, we adopt the NCEP ATP III

definition of MS.

Still others feel that neither BMI nor waist
circumference is particularly useful in diagnosing MS
(Schubert, 2004) . Instead, a high triglyceride level has
been cited as a more precise predictor of MS and CVD,
especially in cases when an individual may appear nonsymptomatic or in cases where there is variation in body
shape due to ethnicity (He et al, 2001).
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Appendix C
Quality Adjusted Life Years

A QALY is a health index that estimates the quantity
and quality of life generated by health care interventions.
QALYs place weight on the time spent in different health
states such that a year of perfect health is assigned a
value of 1 and death is assigned a value of 0.

Some health

states are considered worse than death and are assigned
negative scores (Thompson (2003).

Weinstein and Stason (1977) popularized the term QALY.
QALYs are also referred to as Years of Healthy Life (YHL),
Health Adjusted Person Years (HAPY), Health Adjusted Life
Expectancy (HALE)
Saved (LYS).

(Drummond et al, 2000) and Life-Year

Several other alternatives to QALYs exist.

These include Health Year Equivalents (HYE) and SavedYoung-Life Equivalents (SAVE).

While the HYE has been proposed as a theoretically
superior alternative to the QALY albeit more complex to
execute, the SAVE has been proposed as a more socially
sensitive alternative because it reflects a societal
43

perspective to health utility. QALYs are accused of not
measuring social value because preferences and weights are
based on individualistic perspective rather than a societal
perspective (Drummond et al, 2000; Mehrez and Gafni, 1992
and Nord et al, 1993). Since it is society that ultimately
bears the cost of health care, it would seem more
appropriate if the SAVE is used to measure effectiveness.
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Appendix D

Standard Gamble Approach

When calculating health utilities under the standard
gamble approach (von Neumann and Morgenstern, 1953), an
individual is presented with two choices:

(1) the certainty

of survival for a specific period of time in a particular
state of health and (2) the gamble of survival for the same
period of time without disability on one hand and with
immediate death on the other.

The chance of survival

without disability, as opposed to the chance of death is
varied until the individual is indifferent between
certainty and gambling. This probability then estimates the
utility of the individual for the disabled state (Petrou,
2003) .
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